People · Operator
Named in public records as an officer, director or promoter · active 2021–2021 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cancer Prevention Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $18.0M | $9.7M | 2021 |
John Saxe at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Saxe on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard Love | 1 | 5 |
| Jon Saxe | 1 | 4 |
| Andrew Levitch | 1 | 3 |
| Jeffrey E Jacob | 1 | 2 |
| Eugene Gerner, Ph.D. | 1 | 1 |
| Daniel Donovan | 1 | 1 |
| Frank Meyskens | 1 | 1 |
| Eugene W Gerner | 1 | 1 |
| Frank W Meyskens | 1 | 1 |
| Richard W Love | 1 | 1 |
| Daniel W Donovan | 1 | 1 |
| Jeffrey Jacob | 1 | 1 |
| Christopher Richied | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.